DOGZ:NASDAQDogness (International) Corporation Analysis
Data as of 2026-03-29 - not real-time
$1.38
Latest Price
8/10Risk
Risk Level: High
Executive Summary
DOGZ trades at $1.38, well below its 20‑day SMA of 1.51 and far beneath the 50‑day SMA of 2.64, indicating a prolonged downtrend. The 200‑day SMA sits near 10.31, underscoring the depth of the current weakness. RSI is at 28, technically oversold yet the price continues to slip. MACD shows a bullish histogram despite the overall bearish momentum, hinting at a possible short‑term reversal. Volume is trending lower, supporting the bearish bias. Volatility over the past 30 days exceeds 68%, and the stock has endured a historic max drawdown of roughly 96%, reflecting extreme price swings. The DCF‑derived fair value of $0.33 is less than a quarter of the market price, flagging the stock as overvalued. A price‑to‑book of 0.20 suggests cheapness relative to assets, but the company’s debt‑to‑equity ratio of 15.6 and negative operating margin of ‑50.8% raise solvency concerns. Earnings are negative (trailing EPS –0.38) and there is no dividend, making dividend sustainability a non‑issue. The Fear & Greed index reads 66 (“Greed”), indicating market optimism despite weak fundamentals. Overall, the confluence of technical weakness, high volatility, and deteriorating fundamentals paints a bleak near‑term outlook.
Given the bearish technical setup, high volatility, and substantial debt load, the stock carries a high overall risk rating. Geographic exposure to China adds regulatory and market‑specific uncertainties. Consequently, a short‑term sell recommendation is warranted, with a medium‑term hold for investors awaiting a clear turnaround, and a long‑term sell due to the structural challenges.
Given the bearish technical setup, high volatility, and substantial debt load, the stock carries a high overall risk rating. Geographic exposure to China adds regulatory and market‑specific uncertainties. Consequently, a short‑term sell recommendation is warranted, with a medium‑term hold for investors awaiting a clear turnaround, and a long‑term sell due to the structural challenges.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- Price below 20‑day and 50‑day SMAs
- RSI in oversold territory yet momentum remains bearish
- Decreasing volume amid high volatility
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Negative earnings and margins
- High debt‑to‑equity ratio
- Potential upside if a turnaround in operating cash flow occurs
Long Term
> 3 yearsCautious
Model confidence: 6/10
Key Factors
- Historical max drawdown of ~96%
- Unsustainable cash burn and lack of dividend
- Regulatory and market uncertainty in China
Key Metrics & Analysis
Financial Health
Revenue Growth5.50%
Profit Margin-24.63%
ROE-5.86%
ROA-3.80%
Debt/Equity15.59
P/B Ratio0.2
Op. Cash Flow$567.1K
Free Cash Flow$431.0K
Technical Analysis
TrendBearish
RSI28.1
Support$1.30
Resistance$1.75
MA 20$1.51
MA 50$2.64
MA 200$10.31
MACDBullish
VolumeDecreasing
Fear & Greed Index65.98
Valuation
Fair Value$0.33
GradeOvervalued
TypeValue
Risk Assessment
Beta0.45
Volatility68.88%
Sector RiskMedium
Reg. RiskHigh
Geo RiskHigh
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.